Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 7, Issue 4, Pages 555-568Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.7.4.555
Keywords
affibody molecules; HER2; molecular imaging; personalized medicine; radionuclide targeting
Ask authors/readers for more resources
Targeting radionuclide imaging of tumor-associated antigens may help to select patients who will benefit from a particular biological therapy. Affibody (R) molecules are a novel class of small (similar to 7 kDa) phage display-selected affinity proteins, based on the B-domain scaffold of staphylococcal protein A. A large library (3 x 10(9) variants) has enabled selection of high-affinity (up to 22 pM) binders for a variety of tumor-associated antigens. The small size of Affibody molecules provides rapid tumor localization and fast clearance from nonspecific compartments. Preclinical studies have demonstrated the potential of Affibody molecules for specific and high-contrast radionuclide imaging of HER2 in vivo, and pilot clinical data using indium-111 and gallium-68 labeled anti-HER2 Affibody tracer have confirmed its utility for radionuclide imaging in cancer patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available